Changes

NIH royalties (view source)

Revision as of 01:02, April 11, 2022

622 bytes added , 01:02, April 11, 2022

The vaccine mandates at school for HPV boosted NIH revenues

Line 1: Line 1:

'''NIH royalties''' on its [[patent]]s can enrich the bureaucracy and its officers.

−

Since 2017, the royalty income has been declining, which have increased the pressure at the [[NIH]] to push for patentable ~~patents~~ rather than inexpensive medications for treating [[COVID-19]].<ref>https://www.ott.nih.gov/metrics/royalty-income</ref>

+

Since 2017, the royalty income has been declining, which have increased the pressure at the [[NIH]] to push for patentable [[vaccine]]s rather than inexpensive medications for treating [[COVID-19]].<ref>https://www.ott.nih.gov/metrics/royalty-income</ref>

+

The vaccine mandates at school for [[HPV]] boosted NIH revenues:

+

{{cquote|And the three best-selling products utilizing technology licensed from NIH [in 2014] were Janssen’s Prezista, a novel protease inhibitor for the treatment of HIV-1 in patients who are non-responsive to existing antiretroviral therapies, Merck’s Gardasil, a vaccine to protect against cervical cancer, and AstraZeneca’s Synagis, a monoclonal antibody for the treatment of Respiratory Syncytial Virus (RSV) in infants.<ref>https://www.raps.org/news-and-articles/news-articles/2019/4/how-biopharma-companies-use-nih-and-vice-versa</ref>}}

== References ==

[[category:patent law]]

Aschlafly

Anthony, Irenaeus, Siteadmin, apieditor, Bureaucrats, Check users, nsAm_Govt_101RO, nsAm_Govt_101RW, nsAm_Govt_101_ta, nsJudgesRO, nsJudgesRW, nsJudges_talkRO, nsJudges_talkRW, nsTeam2RO, nsTeam2RW, nsTeam2_talkRO, nsTeam2_talkRW, oversight, Administrators

126,204

edits

Changes

NIH royalties (view source)

Revision as of 01:02, April 11, 2022

Navigation menu

Search